Court says GW did not violate patent

A U.S. court found GW Pharmaceuticals did not violate a patent owned by cannabis giant Canopy Growth. The ruling, in a 2020 case brought by Canopy Growth, claimed GW, maker of the high-CBD drug Epidiolex, was handed down by a federal district court in Texas. Ontario-based Canopy Growth had alleged that GW appropriated its patented cannabis extraction method. GW Pharmaceuticals is owned by Dublin, Ireland-based Jazz Pharmaceuticals, which purchased the UK-based company last year for $7.2 billion in cash and stock. It’s not known if Canopy Growth intends to appeal the decision.